Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Completed No phase listed Observational

Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes

NCT00446355
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa

NCT05927948
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Laight therapy, NICE V3.1 device
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Physical Activity in Hidradenitis Suppurativa (HS)

NCT06015438
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Home Exercise Program, Short Exercise Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2014 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effect of Jublia on Dermatophytomas

NCT03098615
View directory record Official record
Conditions
Onychomycosis, Dermatophytosis
Interventions
Jublia (Efinaconazole 10% Topical Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 22, 2026, 6:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT06511050
View directory record Official record
Conditions
Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Lumbrokinase
Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Not yet recruiting Phase 2 Interventional

Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

NCT07804368
View directory record Official record
Conditions
Coccidioidomycosis, Blastomycosis, Histoplasmosis, Dimorphic Fungal Infection, Endemic Mycoses
Interventions
Oteseconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Tempe, Arizona • Davis, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

NCT00396578
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Respiratory Infection, Tracheobronchitis
Interventions
aerosolized vancomycin or gentamicin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

NCT00728260
View directory record Official record
Conditions
Meningitis, Meningococcal Disease
Interventions
None administered in this study
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
View directory record Official record
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT04094883
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Meningococcal Group B Vaccine
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Early Phase 1 Interventional Results available

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

NCT05027958
View directory record Official record
Conditions
Healthy, Latent Tuberculosis Infection (LTBI)
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

NCT03572049
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
SUBA itraconazole, Conventional itraconazole
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational

Immune Profiles in CF Fungal Infection

NCT04476758
View directory record Official record
Conditions
Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 25 Years
Enrollment
24 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 6:07 AM EDT
Recruiting Early Phase 1 Interventional

Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis

NCT07830771
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational

A Registry of Tuberculosis Cases in the CPCRA

NCT00000785
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
1,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
13
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044
View directory record Official record
Conditions
Dysentery, Diarrhea, Enteric Campylobacteriosis
Interventions
Rifaximin intervention, Placebo intervention
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 22, 2026, 6:07 AM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT05819398
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

NCT04075175
View directory record Official record
Conditions
Diphtheria
Interventions
S315, 0.9% Sodium Chloride (NaCl)
Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 6:07 AM EDT